Surgical & Medical Robots: The Ultimate Guide
How surgical robots actually work: master-slave teleoperation, motion scaling, haptic orthopedics, FDA clearance, economics, and the limits of autonomy.
A surgical robot does not operate on anyone. That sentence is the whole legal and engineering foundation of the field, and it is worth stating before anything else. The da Vinci system that has done more than twenty million procedures is a teleoperator: a surgeon sits at a console a few meters from the patient, moves two hand controllers, and the robot reproduces those motions inside the body through instruments the diameter of a pencil. The machine adds no intent. It scales the surgeon's hand motion down by a factor of three to five, filters out the physiological tremor in the surgeon's fingers, and passes the result to wristed instruments that bend in ways a human wrist trapped inside a 8 mm port never could. Every millimeter the instrument moves traces back to a millimeter the surgeon's hand moved. The autonomy is zero by design, and in most of the installed base it is zero by regulation.
That framing splits the field cleanly. On one side sit the master-slave teleoperated systems, da Vinci and its new competitors, where the robot is a motion-faithful extension of a human. On the other sit the hands-on and semi-active systems, the orthopedic robots like Stryker's Mako, where the surgeon holds the cutting tool directly and the robot's job is to stop them from cutting outside a plan. In between and around the edges are catheter and endoluminal robots that drive through blood vessels and airways, flexible robots that snake through natural orifices, and a large quieter category of non-surgical medical robots: rehabilitation exoskeletons, pharmacy dispensing arms, UV disinfection towers, and the hospital logistics robots that move linens and meals down corridors at night.
This guide treats the surgical robot as the safety-critical teleoperator it is. We work through the archetypes, the enabling technology that makes remote manipulation feel like direct manipulation (motion scaling, tremor filtering, force feedback, 3D vision, precision kinematics), the regulatory reality that governs every design decision, the non-surgical robots that quietly outnumber the surgical ones, the economics that decide whether a hospital buys, the companies that build these machines, and the hard ceiling on autonomy that keeps a human hand on every instrument.
The take: A surgical robot is a safety-critical teleoperator whose entire value is fidelity, taking a surgeon's hand motion and reproducing it inside the body with less tremor, more dexterity, and a magnified 3D view, while adding no autonomy of its own. The technology that matters is the chain from console to instrument tip: motion scaling and tremor filtering at the input, low-friction precision kinematics and remote-center-of-motion mechanics in the middle, and 3D stereo vision closing the loop for the surgeon. The economics turn on a razor-and-blade model where the capital cost of the robot is dwarfed over its life by per-procedure disposable instruments, and the regulatory ceiling on autonomy is the operating premise itself: the surgeon holds liability, so the surgeon holds control.
Companion reading: robot calibration, robot safety & functional safety, real-time control systems, end-effectors & grippers, robot sensors, and industrial robot arms.
Table of contents
- Key takeaways
- The archetypes: four ways to build a surgical robot
- Master-slave teleoperation and da Vinci
- The enabling technology chain
- Hands-on and haptic orthopedic robots
- Catheter, endoluminal, and flexible robots
- The regulatory reality: clearance, safety, liability
- Non-surgical medical robots
- Economics and adoption
- The players
- Outlook and the limits of autonomy
- Frequently asked questions
The archetypes: four ways to build a surgical robot
Start with the taxonomy, because the control architecture, the regulatory path, and the business model all follow from which archetype you are building. There are four.
Master-slave teleoperated systems are the ones most people picture. The surgeon sits at a console, physically separated from the patient, and manipulates hand controllers (masters). Robotic arms at the patient (the slaves, in the field's older but still standard terminology) hold and drive instruments that enter through small ports. The console-to-arm link is entirely electronic. This is da Vinci, Medtronic's Hugo, CMR Surgical's Versius, and Johnson & Johnson's Ottava. The archetype targets soft-tissue minimally invasive surgery: urology (prostatectomy is the anchor procedure), gynecology, general surgery, thoracic.
Hands-on and semi-active haptic systems invert the relationship. The surgeon holds the working instrument directly, a bone saw or a drill or a burr, and the robot constrains motion. It builds a patient-specific plan from a preoperative CT scan, defines a three-dimensional boundary (a haptic or virtual wall), and lets the surgeon move freely inside the plan while resisting or halting motion at the boundary. Stryker's Mako for knee and hip replacement is the archetype. The robot never moves on its own; it stops the surgeon from moving wrong.
Catheter and endoluminal robots drive flexible instruments through the body's natural lumens: blood vessels, airways, the urinary tract. There are no incisions. A robotic drive at the bedside advances, rotates, and articulates a catheter or bronchoscope while the physician works from a workstation. Auris/Johnson & Johnson's Monarch (lung biopsy) and Intuitive's Ion (also lung) are the archetypes, along with robotic systems for cardiac electrophysiology and percutaneous coronary intervention.
Flexible and continuum robots are the research-heavy frontier: snake-like or concentric-tube manipulators that bend continuously along their length to reach through a single natural orifice and around anatomy that a rigid instrument cannot. Some transoral and transanal platforms are commercial; much of the field is still in trials.
| Archetype | Control relationship | Access | Anchor procedures | Example systems |
|---|---|---|---|---|
| Master-slave teleoperated | Surgeon at console, robot reproduces motion | Small ports (laparoscopic) | Prostatectomy, hysterectomy, hernia | da Vinci, Hugo, Versius, Ottava |
| Hands-on / semi-active haptic | Surgeon holds tool, robot constrains | Open or mini-open | Knee/hip replacement, spine | Mako, ROSA, CORI |
| Catheter / endoluminal | Physician at workstation, robot drives catheter | Natural lumens, no incision | Lung biopsy, cardiac ablation, PCI | Monarch, Ion, robotic EP |
| Flexible / continuum | Teleoperated flexible manipulator | Single orifice | Transoral, transanal (emerging) | Research + early commercial |
Master-slave teleoperation and da Vinci
The teleoperated archetype dominates the installed base and the public imagination, so it is worth understanding in mechanical detail. Intuitive Surgical shipped the first da Vinci in 2000 after FDA clearance, and by 2026 the installed base exceeds eleven thousand systems worldwide with cumulative procedures past twenty million. The current flagship is the da Vinci 5, cleared in 2024, alongside the widely deployed Xi and the single-port SP.
A da Vinci has three physical pieces. The surgeon console is where the operator sits, looking into a stereo viewer and gripping two master controllers, with foot pedals for clutching, camera control, and energy instruments. The patient cart carries three or four robotic arms that dock to ports in the patient; one arm holds the endoscope, the others hold instruments. The vision cart houses the image processing, insufflation, and light source. The console and cart are linked electronically, so the surgeon has no direct mechanical connection to the patient.
The mechanical trick that makes port surgery possible is the remote center of motion (RCM). Every instrument must pivot about the point where it passes through the body wall; move that pivot and you tear the incision. The RCM is a mechanical constraint, usually a parallelogram linkage or a pair of coupled arcs, that forces the instrument to rotate about a fixed point in space located at the port, without any active control effort to hold it there. The kinematics enforce it. Inside the body, the instrument ends in a wrist (Intuitive's EndoWrist) that adds articulation the straight laparoscopic tool lacks, giving the instrument tip a full seven degrees of freedom: three to position the tip, three to orient it, and one to open and close the jaws. That wrist is why a robot can suture at an angle in a deep pelvis where a rigid laparoscopic needle driver cannot reach.
The value proposition is dexterity and visualization inside a minimally invasive footprint. The surgeon gets an immersive magnified 3D view, wristed instruments that restore the dexterity lost when you switch from open surgery to laparoscopy, an ergonomic seated posture instead of hours hunched over a table, and the software layer that scales and de-tremors their motion. The tradeoffs are real: high capital and per-case cost, setup and docking time, a footprint that crowds the operating room, and the loss of direct tactile feedback.
Rule of thumb: The teleoperated robot earns its cost where the anatomy is deep, confined, and demands fine reconstruction (suturing, dissection near vessels and nerves). It earns the least on procedures a skilled laparoscopist already does quickly through standard ports.
The enabling technology chain
What makes remote manipulation feel like direct manipulation is a chain of specific technologies from the surgeon's hand to the instrument tip. Each link matters, and a failure in any one breaks the illusion of presence.
Motion scaling maps a large hand motion to a small instrument motion, typically 3:1 to 5:1, selectable. Move your hand three centimeters and the tip moves one. This is what lets a surgeon work at sub-millimeter precision using the natural range of their arm, and it is a pure software transform on the master's measured position.
Tremor filtering removes the involuntary physiological tremor every human hand carries, a roughly 8 to 12 Hz oscillation of a few tens to hundreds of microns. The controller low-pass or notch filters the master's motion signal in that band before commanding the slave, so the tremor never reaches the tissue. Combined with motion scaling, which shrinks the tremor amplitude along with everything else, the instrument tip is steadier than any unaided hand.
Precision kinematics and low friction in the arms are what let the tip actually go where the math says. The arms use cable or capstan drives and harmonic or precision gearing, calibrated so that the forward kinematics (joint angles to tip pose) and their inverse are accurate to fractions of a millimeter across the workspace. Backlash, cable stretch, and friction are the enemies of fidelity, and much of the calibration effort in these machines goes into characterizing and compensating them. The RCM constraint discussed above is part of this link.
3D stereo vision closes the perceptual loop. A dual-channel endoscope feeds two offset images to a stereo viewer, giving the surgeon binocular depth. High-end systems now run 4K per eye with digital zoom and fluorescence imaging modes (near-infrared with a fluorescent dye) that light up blood flow, bile ducts, or tumor margins the naked eye cannot see. The depth cue is essential; suturing and dissection depend on judging depth, and monocular laparoscopy loses it.
Force feedback (haptics) is the link that first-generation systems mostly left out. The original da Vinci gave the surgeon almost no sense of how hard an instrument was pulling on tissue; the surgeon inferred force from visual cues (tissue blanching, suture deformation). Restoring haptic feedback means measuring instrument-tip forces and reflecting them to the master controllers, which is hard: the force sensors have to survive sterilization and fit inside an 8 mm instrument, and the control loop has to be stable while reflecting force across the electronic link. This is an active frontier, and newer systems including da Vinci 5 have begun introducing force sensing and feedback. For the sensing side of this problem see robot sensors; for the safety-critical control loop underneath it see real-time control systems.
The instrument tip itself is a specialized end-effector: needle drivers, graspers, scissors, monopolar and bipolar energy tools, staplers, each a wristed disposable or semi-disposable unit with a programmed usage limit.
War story: An early complaint about the first da Vinci was surgeons snapping sutures because they could not feel the thread tension. The fix that stuck came from training and visual discipline instead of a force sensor: watch the tissue and the suture loop, and read force with your eyes. A generation of robotic surgeons learned to operate by sight alone. The lesson is that the missing haptic link was survivable, but only because vision was good enough to substitute, and that substitution shaped how the whole specialty was taught.
Hands-on and haptic orthopedic robots
Orthopedic surgery took a different path because the problem is different. Bone is rigid, the target geometry is known from a preoperative CT scan, and the task is to cut or ream bone to a precise plan so an implant seats correctly. That plays to a robot's strength (geometric precision) while sidestepping the hard part of soft-tissue surgery (deforming, unpredictable anatomy).
Stryker's Mako is the reference system for robotic-arm-assisted joint replacement (total knee, partial knee, total hip). The workflow: a preoperative CT builds a 3D model of the patient's bone; the surgeon plans implant size and position on that model; intraoperatively the system registers the plan to the actual bone using tracked arrays; then the surgeon guides a robotic arm holding a saw or burr, and the arm enforces a haptic boundary. Inside the planned volume the arm moves freely with the surgeon's hand. At the boundary it resists, and it will physically stop the cutting tool from crossing the plane that protects ligaments, vessels, and healthy bone. The surgeon does the cutting; the robot guarantees they cannot cut where they should not.
This is a fundamentally safer autonomy story than teleoperation, and it clears regulators more easily, because the human is always in direct physical control of the energy tool and the robot's authority is purely restrictive. The robot can only prevent motion, never command it. Zimmer Biomet's ROSA (knee, hip, and a separate spine and brain platform) and Smith+Nephew's CORI (a handheld robotic burr with a control loop that retracts the cutter outside the plan) compete in the same space with variations on the theme. Spine robots (Medtronic's Mazor, Globus Medical's ExcelsiusGPS) apply the same idea to pedicle screw placement: plan on imaging, then constrain or guide the drill trajectory.
The adoption argument in orthopedics is concrete: better implant alignment, more reproducible outcomes, and a selling point for hospitals competing for joint-replacement volume. The debate is whether the alignment gains translate to enough long-term outcome and revision-rate benefit to justify the capital and per-case cost, and the evidence there is still maturing.
Catheter, endoluminal, and flexible robots
The endoluminal archetype removes the incision entirely by driving flexible instruments through the body's own passages. Two forces push this direction: patient benefit (no cut, faster recovery) and the ergonomic and radiation problems of the physician doing these procedures by hand.
Robotic bronchoscopy is the clearest success. Reaching a small nodule in the lung periphery to biopsy it means steering a bronchoscope through many airway branches, and doing it by hand is imprecise and hard to reproduce. Auris Health's Monarch (now Johnson & Johnson) and Intuitive's Ion both drive an articulating catheter to the target under image guidance, holding position steadily while the biopsy is taken. The robot's steadiness and the software's registration of the catheter tip to a preoperative CT map improve reach and reproducibility in the lung periphery.
Robotic cardiac and vascular systems drive catheters through blood vessels for electrophysiology (ablating tissue to treat arrhythmia) and for percutaneous coronary intervention (stenting). A major and underappreciated driver here is radiation: these procedures are guided by continuous X-ray fluoroscopy, and the interventional cardiologist stands beside the table for years wearing heavy lead. A robotic catheter drive lets the physician sit in a shielded cockpit away from the beam, which is a real occupational-health argument independent of any precision benefit.
Flexible and continuum robots are the research frontier and the hardest control problem in the field. A continuum manipulator has no discrete joints; it bends continuously, often built as concentric pre-curved tubes that rotate and translate relative to each other, or as a tendon-driven backbone. The kinematics are nonlinear and the shape depends on the forces the environment applies, so estimating and controlling the tip pose is genuinely hard. The payoff is reaching around anatomy through a single small opening. Some transoral robotic surgery platforms are commercial; much of the continuum-robot work remains in labs and early trials. This is where the mechanical creativity of the field lives, and where soft robotics ideas meet surgery.
The regulatory reality: clearance, safety, liability
No design decision in this field is made without the regulator in the room. A surgical robot is a Class II or Class III medical device, and the pathway to market shapes the architecture as much as any engineering constraint.
In the US, the FDA offers three main routes. 510(k) clearance is the workhorse: you show your device is substantially equivalent to a legally marketed predicate. Most surgical robots and instruments reach the market this way, building on the enormous predicate history da Vinci established. De Novo classification handles novel devices with no predicate but low-to-moderate risk. PMA (premarket approval), the most stringent path, applies to the highest-risk Class III devices and requires clinical evidence of safety and effectiveness. In the EU, the equivalent framework is the Medical Device Regulation (MDR), which tightened evidence requirements substantially over the prior directive.
Underneath the clearance sits a functional-safety discipline that mirrors industrial robotics but with a patient in the loop. The relevant standards include IEC 60601 for medical electrical equipment, IEC 62304 for medical device software lifecycle, and ISO 14971 for risk management. The design has to assume components fail and guarantee the failure is safe: an arm that loses power must not lurch, an instrument that faults must hold or release predictably, and the software has to be developed and documented to a lifecycle standard that an auditor can trace. This is the same discipline covered in functional safety, applied where the workspace is a human body.
The deepest constraint is liability, and it is not primarily technical. In every jurisdiction, the surgeon or physician holds legal responsibility for the procedure and its outcome. That single fact is the structural reason autonomy stays near zero: a robot that made an independent surgical decision would create a liability that no manufacturer wants to hold and no current legal framework knows how to assign. Keeping a human in direct control of every cut keeps responsibility where the law already puts it. The autonomy ceiling is a liability ceiling first and an engineering ceiling second.
Safety rule: In a surgical robot the anatomy defines the fail-safe state. An industrial arm fails safe by stopping and holding. A surgical instrument inside a patient may need to hold, retract, or de-energize depending on where it is and what it is touching. The hazard analysis has to reason about the tissue, which is why medical robotics safety cases are longer and harder than industrial ones.
Non-surgical medical robots
The robots that touch the most patients are not surgical. A large and faster-growing category does the logistical, rehabilitative, and hygienic work of a hospital, and it faces lighter regulation and clearer labor-savings math.
Rehabilitation robots and exoskeletons help patients relearn movement after stroke or spinal injury, or restore mobility for people with paralysis. Powered lower-limb exoskeletons (Ekso Bionics, ReWalk, and others) let some spinal-cord-injury patients stand and walk in therapy; upper-limb and gait-training robots deliver the high-repetition guided movement that drives neuroplastic recovery, more consistently than a therapist can by hand. This overlaps directly with the exoskeletons field.
Pharmacy automation is quietly one of the highest-value robotics deployments in healthcare. Robotic systems compound sterile IV medications (including hazardous chemotherapy drugs, where automation protects staff from exposure), count and package pills, and manage dispensing. The value is accuracy (medication errors are a leading cause of patient harm) and staff safety, and the regulatory burden is closer to pharmacy and drug-handling rules than to surgical device law.
Disinfection robots run UV-C germicidal light through rooms between patients to reduce healthcare-associated infections. A mobile robot (Xenex, UVD Robots, and others) parks in a cleaned room and pulses ultraviolet light that damages microbial DNA. Demand surged during the COVID-19 period and the installed base persisted. These are essentially mobile robots with a specialized payload and a safety interlock so no human is exposed to the UV.
Hospital logistics robots move materials so staff do not. Autonomous mobile robots (Aethon's TUG is the long-running example, alongside newer AMR fleets) haul medications, meals, linens, and lab specimens through corridors and elevators, navigating with the same SLAM and obstacle-avoidance stacks as warehouse robots. The economic case is straightforward: nurses and technicians are expensive and scarce, and moving carts is not the work you hired them for. This is mobile-robot technology in a hospital skin.
| Category | Job | Value driver | Example makers |
|---|---|---|---|
| Rehab / exoskeleton | Restore or retrain movement | Therapy consistency, mobility | Ekso, ReWalk, Hocoma |
| Pharmacy automation | Compound, count, dispense drugs | Accuracy, staff safety | Omnicell, BD, ARxIUM |
| UV-C disinfection | Kill pathogens between patients | Infection reduction | Xenex, UVD Robots |
| Logistics AMR | Move materials autonomously | Labor savings, staff focus | Aethon, Diligent (Moxi) |
Economics and adoption
The economics of surgical robotics are dominated by a razor-and-blade model, and understanding it explains the whole market structure. A da Vinci system carries a capital price roughly in the 0.5 to 2.5 million dollar range depending on configuration, but that one-time cost is not where Intuitive Surgical makes most of its money. The larger and more durable revenue comes from recurring per-procedure sales: instruments and accessories consumed each case, plus multi-year service contracts. Intuitive's instruments carry programmed use-count limits (an EndoWrist tool authorizes a fixed number of uses, then locks out), which converts every procedure into a consumable sale. Across the company's revenue, recurring instrument-and-service income substantially exceeds system sales.
This model is why the installed base compounds. Every placed system is an annuity, and the more procedures per system per year, the better the economics for both Intuitive and, arguably, the hospital that has to justify the capital. It also explains competitive strategy: new entrants attack the recurring-revenue lock by offering open consumable ecosystems or lower per-case costs.
For the hospital, the buying decision is harder than the marketing implies. The capital cost, the per-case instrument cost (often one to several thousand dollars above the equivalent laparoscopic case), the operating-room time for setup and docking, and training all weigh against the benefits: shorter length of stay for some procedures, less blood loss, faster recovery, surgeon recruitment and retention, and the marketing value of offering robotic surgery. The evidence that robotic surgery produces better clinical outcomes than expert laparoscopy is genuinely mixed and procedure-dependent; it is strongest where the anatomy is deep and reconstructive (prostatectomy) and weakest where a good laparoscopist is already fast and effective. Much robotic adoption is driven by surgeon preference, patient demand, and competitive positioning as much as by hard outcome data.
Rule of thumb: A surgical robot pays back through volume and case mix, not through any single procedure. A system doing hundreds of well-chosen cases a year amortizes; a system doing a few dozen is a very expensive way to do surgery. Utilization is the number that decides whether the purchase was wise.
Orthopedic robots follow a similar but distinct logic: Stryker sells Mako partly to pull through its implant sales, so the robot is a channel for the high-margin consumable (the implant) as much as a standalone product. The competition among Stryker, Zimmer Biomet, and Smith+Nephew is as much about locking in implant ecosystems as about the robot itself.
The players
The field has one dominant incumbent and a wave of well-funded challengers finally reaching the market after years of delay.
Intuitive Surgical owns the teleoperated soft-tissue market with da Vinci: more than a decade of monopoly, an installed base past eleven thousand systems, and the predicate history and instrument ecosystem that make it hard to displace. Its 2024 da Vinci 5 adds force feedback and more compute. Intuitive also fields Ion for robotic bronchoscopy.
Medtronic entered with Hugo, a modular multi-arm teleoperated system (separate arm carts rather than one big patient cart) aimed at urology and gynecology, deployed internationally and, as of December 2025, cleared by the FDA for urologic procedures in the US. Medtronic's play is its scale, its existing hospital relationships, and its surgical-instrument business.
CMR Surgical, a UK company, builds Versius, a modular teleoperated system with individual portable arm carts designed to fit existing operating rooms and move between them. Versius has meaningful international deployment, particularly in Europe and beyond, and represents the strongest independent challenger.
Johnson & Johnson MedTech is the sleeping giant. It acquired Auris (Monarch bronchoscopy) and the surgical-robotics assets and has developed Ottava, its teleoperated soft-tissue system, which reached clinical trials with a distinctive architecture (arms integrated into the operating table). J&J's combination of the world's largest surgical-instrument business (Ethicon), the Monarch endoluminal platform, and Ottava makes it the competitor Intuitive watches most closely.
Stryker (Mako), Zimmer Biomet (ROSA), and Smith+Nephew (CORI) hold orthopedics. Medtronic (Mazor) and Globus Medical (ExcelsiusGPS) hold spine. Beyond these, dozens of smaller companies and academic spinouts work catheter robotics, flexible endoscopy, microsurgery (Microsure and others for supermicrosurgery), and ophthalmic and dental robots.
The pattern to notice: the incumbents in each segment are the companies that already sold the consumable (the instrument, the implant), and the robot is a way to defend and grow that consumable stream. That is why the big medical-device conglomerates, not pure robotics startups, are Intuitive's real competition.
Outlook and the limits of autonomy
The trajectory of the field is clear in its direction and firmly bounded in its ceiling. Progress is happening at the edges of autonomy while the center stays under human control, and that arrangement is likely to persist for structural reasons rather than technical ones alone.
The near-term advances are augmentation, not replacement. Better imaging and data fusion: fluorescence guidance, intraoperative overlay of preoperative CT and MRI onto the live view, and eventually augmented-reality guidance that shows the surgeon subsurface structures. Restored haptics: force feedback moving from research into product, closing the one obviously missing link in teleoperation. Smaller, cheaper, modular systems: the challengers are competing on footprint and cost to bring robotics to hospitals and procedures da Vinci priced out. Task-level autonomy in constrained subtasks: automated camera control that follows the instruments, robotic knot-tying and suturing demonstrations, and the bone-cutting boundary enforcement that Mako already ships. Research systems like the Smart Tissue Autonomous Robot (STAR) have shown autonomous suturing of soft tissue in animal models, which is a genuine milestone and also a demonstration of how narrow and controlled the successful cases still are.
The ceiling is real and worth stating plainly. Full surgical autonomy, a robot that perceives patient-specific anatomy, decides what to do, and does it on soft deforming tissue without a human in the loop, is blocked by three compounding problems. The perception problem: soft tissue deforms, bleeds, and varies between patients, so the robot cannot rely on a fixed geometric model the way an orthopedic robot relies on rigid bone. The decision problem: surgical judgment integrates a lifetime of pattern recognition and reacts to surprises that no training set covers. The liability problem: even if the first two were solved, the legal system assigns responsibility to a human, and no framework exists to hold a machine or its maker accountable for an autonomous surgical decision. The first two are engineering frontiers that will yield slowly. The third is a policy and legal question that engineering cannot answer.
So the honest outlook is a machine that keeps getting better at being an extension of a surgeon: steadier, more informative, more dexterous, cheaper, and eventually able to run well-defined subtasks under supervision. The surgeon stays in the loop because the whole enterprise is built on the surgeon holding responsibility, even as the technology keeps advancing. A teleoperator that adds capability while keeping a human accountable is the stable form of this technology, and it is the form the field will keep refining.
Frequently asked questions
Does the robot perform the surgery by itself? No. The dominant surgical robots are teleoperators: a surgeon at a console controls every motion in real time, and the robot reproduces that motion inside the body. The robot adds motion scaling, tremor filtering, and instrument dexterity, and adds no autonomous decision-making to the surgery. Orthopedic systems like Mako go a step further by constraining the surgeon's tool to a plan, but the surgeon still does the cutting.
What is the difference between da Vinci and Mako? They are different archetypes. Da Vinci is a master-slave teleoperated system for soft-tissue surgery: the surgeon sits at a console and the robot's arms reproduce their hand motion through ports. Mako is a hands-on haptic system for joint replacement: the surgeon holds a bone-cutting tool directly and the robotic arm physically stops them from cutting outside a CT-based plan. One reproduces motion, the other constrains it.
Why is there no force feedback on many surgical robots? Because measuring instrument-tip forces inside an 8 mm sterilizable instrument and reflecting them stably across an electronic link is genuinely hard, and the first-generation da Vinci shipped without it. Surgeons learned to read force visually from tissue deformation and suture tension. Restoring true haptic feedback is an active frontier, and newer systems including da Vinci 5 have begun adding force sensing.
How much does a surgical robot cost? A teleoperated system like da Vinci runs roughly 0.5 to 2.5 million dollars in capital depending on configuration, but that is not the main cost over its life. The manufacturer earns most revenue from recurring per-procedure instruments (which have programmed use limits) and multi-year service contracts. A hospital should evaluate total cost per case and utilization, well beyond the sticker price.
Is robotic surgery better than conventional or laparoscopic surgery? It depends on the procedure. The benefit is strongest where anatomy is deep and reconstructive, such as prostatectomy, where robotic dexterity and 3D vision clearly help. For procedures a skilled laparoscopist already does quickly, the outcome evidence is mixed and the added cost and setup time may not be justified. Much adoption is driven by surgeon preference and patient demand as much as by hard outcome data.
What regulatory approval do these devices need? In the US, most reach the market through the FDA 510(k) pathway (substantial equivalence to a predicate), with De Novo for novel low-to-moderate-risk devices and PMA for the highest-risk ones. They must also meet functional-safety and software-lifecycle standards (IEC 60601, IEC 62304, ISO 14971). In the EU, the Medical Device Regulation governs, with tighter evidence requirements than the old directive.
Can a surgical robot operate remotely over long distances? Technically the console and patient cart are already linked electronically, and telesurgery over a network has been demonstrated (the 2001 Lindbergh operation across the Atlantic being the famous first). In practice, latency, reliability, and liability keep clinical use local: the surgeon is in the same room. Newer low-latency networks have revived interest, and some longer-distance procedures have been reported, but routine remote surgery is not yet standard.
What are the non-surgical medical robots I should know about? Rehabilitation robots and powered exoskeletons that retrain or restore movement, pharmacy automation that compounds and dispenses drugs (protecting staff from hazardous compounds), UV-C disinfection robots that reduce hospital infections, and autonomous logistics robots that move medications, meals, and linens through hospital corridors. These touch more patients than surgical robots do and face lighter regulation.
Why will full surgical autonomy take so long? Three compounding barriers. Perception: soft tissue deforms, bleeds, and varies between patients, defeating the fixed geometric models that make orthopedic robots reliable. Decision: surgical judgment handles surprises no training set covers. Liability: the legal system assigns responsibility to a human, and no framework exists to hold a machine accountable for an autonomous surgical decision. Engineering will chip away at the first two; the third is a policy question.
